May 16, 2018

Trump Announces intention of Stopping Pharma Companies From ‘Gaming’ Patent System


Recently, US President Trump announced in a White House speech his intention to “take steps” to lower drug prices by stopping “gaming of regulatory and patent processes by drug makers to unfairly protect monopolies,” as well as increasing price transparency and promoting biosimilars and generics. But to do this, his administration will take on what it sees as “freeloading” on US innovation by foreign governments, and addressing “unfair” intellectual property and market access policies in trade agreements.

The plan as outlined appears to offer some proposals, such as updating a drug database for greater transparency, possibly requiring prices to appear with drug ads, and making generics free for low-income senior citizens. And the administration also will publish “a comparison of drug prices in the United States with those in other OECD countries, to examine freeloading,” it says.

But public health advocates reacted strongly to the announcement, saying it may only exacerbate problems of medicines access at home and worldwide.

(Credit: IP Watch)

Related Post

latest News

  • ‘Arbitral award can straightaway be filed and executed in the Court where the assets are located’: SC

    On February 15, the Supreme Court delivered a significant judgement, thereby putting at rest a difference of legal opinion between several High Courts...

    Read More
  • Compose comprehensive policy to cease stubble burning: NGT

    On February 20, the National Green Tribunal (NGT) directed Delhi and four northern states to formulate a comprehensive policy for providing incentives...

    Read More
  • Tata Sons makes a strong case against grant of waiver to Cyrus Mistry

    The Mumbai bench of National Company Law Tribunal (NCLT) held as “not maintainable” the oppression and mismanagement suit filed by the ousted Cyru...

    Read More